Literature DB >> 2072463

Identification of a uniquely immunodominant, cross-reacting site in the human immunodeficiency virus endonuclease protein.

E Björling1, G Utter, P Stålhandske, E Norrby, F Chiodi.   

Abstract

One of the features of the life cycle of retroviruses is insertion of the proviral DNA into host chromosomes. A protein encoded by the 3' end of the pol gene of the virus genome has been shown to possess endonuclease activity (D. P. Grandgenett, A. C. Vora, and R. D. Schiff, Virology 89:119-132, 1978), which is necessary for DNA integration. Sera from the majority of human immunodeficiency virus (HIV)-infected individuals react with endonuclease protein p31 in serological tests (J. S. Allan, J. E. Coligan, T.-H. Lee, F. Barin, P. J. Kanki, S. M'Boup, M. F. McLane, J. E. Groopman, and M. Essex, Blood 69:331-333, 1987; E. F. Lillehoj, F. H. R. Salazar, R. J. Mervis, M. G. Raum, H. W. Chan, N. Ahmad, and S. Venkatesan, J. Virol. 62:3053-3058, 1988; K. S. Steimer, K. W. Higgins, M. A. Powers, J. C. Stephans, A. Gyenes, G. George-Nascimento, P. A. Liciw, P. J. Barr, R. A. Hallewell, and R. Sanchez-Pescador, J. Virol. 58:9-16, 1986). It is not known, however, which part of the protein represents the target(s) for antibody response. To study this, we synthesized peptides and used them in an enzyme-linked immunosorbent assay system to map the reactivity of human immunodeficiency virus type 1 (HIV-1) antibody-positive sera to the different regions of the HIV endonuclease. A uniquely antigenic, HIV-1- and HIV-2-cross-reacting site was identified in the central part of this protein from Phe-663 to Trp-670.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2072463      PMCID: PMC248902          DOI: 10.1128/JVI.65.8.4543-4546.1991

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  15 in total

1.  A 32,000-dalton nucleic acid-binding protein from avian retravirus cores possesses DNA endonuclease activity.

Authors:  D P Grandgenett; A C Vora; R D Schiff
Journal:  Virology       Date:  1978-08       Impact factor: 3.616

2.  Immunogenic nature of a Pol gene product of HTLV-III/LAV.

Authors:  J S Allan; J E Coligan; T H Lee; F Barin; P J Kanki; S M'Boup; M F McLane; J E Groopman; M Essex
Journal:  Blood       Date:  1987-01       Impact factor: 22.113

3.  Detection of antibodies to human T-lymphotropic virus type III by using a synthetic peptide of 21 amino acid residues corresponding to a highly antigenic segment of gp41 envelope protein.

Authors:  J J Wang; S Steel; R Wisniewolski; C Y Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

4.  Human B-cell epitopes of HIV-2 transmembrane protein are similarly spaced as in HIV-1.

Authors:  J Goudsmit; R H Meloen; R Brasseur; F Barin
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1989

5.  Specific binding of tryptophan transfer RNA to avian myeloblastosis virus RNA-dependent DNA polymerase (reverse transcriptase).

Authors:  A Panet; W A Haseltine; D Baltimore; G Peters; F Harada; J E Dahlberg
Journal:  Proc Natl Acad Sci U S A       Date:  1975-07       Impact factor: 11.205

6.  Discrimination between antibodies to HIV and to related retroviruses using site-directed serology.

Authors:  E Norrby; G Biberfeld; F Chiodi; A von Gegerfeldt; A Nauclér; E Parks; R Lerner
Journal:  Nature       Date:  1987 Sep 17-23       Impact factor: 49.962

7.  Comparison of linear antigenic sites in the envelope proteins of human immunodeficiency virus (HIV) type 2 and type 1.

Authors:  E Norrby; P Putkonen; B Böttiger; G Utter; G Biberfeld
Journal:  AIDS Res Hum Retroviruses       Date:  1991-03       Impact factor: 2.205

8.  Purification and structural characterization of the putative gag-pol protease of human immunodeficiency virus.

Authors:  E P Lillehoj; F H Salazar; R J Mervis; M G Raum; H W Chan; N Ahmad; S Venkatesan
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

9.  Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.

Authors:  T J Palker; M E Clark; A J Langlois; T J Matthews; K J Weinhold; R R Randall; D P Bolognesi; B F Haynes
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

10.  Endodeoxyribonuclease activity associated with Rauscher murine leukemia virus.

Authors:  J J Kopchick; J Harless; B S Geisser; R Killam; R R Hewitt; R B Arlinghaus
Journal:  J Virol       Date:  1981-01       Impact factor: 5.103

View more
  2 in total

1.  Monoclonal antibodies against human immunodeficiency virus type 1 integrase: epitope mapping and differential effects on integrase activities in vitro.

Authors:  B M Nilsen; I R Haugan; K Berg; L Olsen; P O Brown; D E Helland
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

2.  Major antigenic region on the integrase (IN) protein of human immunodeficiency virus type 1 determined by reactivity of human sera and a monoclonal antibody to IN protein.

Authors:  Y Tachibana; A Yasuda; T Kurata; S Oka; K Shimada; A Kojima
Journal:  Clin Diagn Lab Immunol       Date:  1994-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.